ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Analyst / Institutional Investor''s Conference27-05-2024
27-05-2024
Zydus Lifesciences completes enrolment for clinical trial of Usnoflast
The company informed that ALS is a rare, progressive, and fatal neurodegenerative disease with an average life expectancy of 3 to 5 years from symptom onset24-05-2024
Zydus Lifesciences Gets USFDA Nod For Asthma Treatment Drug
The approval by the US Food and Drug Administration is for Theophylline extended-release tablets of strengths 300 mg and 450 mg.22-05-2024
Zydus LifeSciences Q4 Results Review - Niche Products, Superior Execution Boost Earnings: Motilal Oswal
Levers in place to improve business prospects over next two-three years20-05-2024
Net profit of Zydus Lifesciences jumps 97%
Net zooms driven by strong performance and strategic investments17-05-2024
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Transcript of the Earnings Conference Call held on May 14, 202417-05-2024
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication with regard to audited financial results for the quarter and year ended on March 31, 202415-05-2024
Zydus Wellness Q4 Results Review - Healthy Performance Paints A Better Long-Term Outlook; Buy: Anand Rathi
We retain our long-term view of a double-digit revenue CAGR and margins returning to 18-20% over two-four years.15-05-2024
Zydus Wellness Results Earnings Call for Q4FY24
Conference Call with Zydus Wellness Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.14-05-2024
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of Investor call on audited financial results for the quarter and year ended on March 31, 202414-05-2024